Drug Interaction Report
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- thiotepa
- trofinetide
Drug interactions
Moderate drug interactions
Moderate:thiotepa trofinetide
Applies to: thiotepa, trofinetide
Trofinetide may alter the blood levels thiotepa which may make it less effective in treating your cancer.
You may also have increased side effects such as nausea, vomiting, mouth ulcers, skin conditions, and low blood cell counts, which can make you more likely to develop anemia, bleeding problems, and infections.
Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you more closely.
Contact your doctor if you experience potential signs and symptoms of these conditions such as:
- paleness of skin
- fatigue
- dizziness
- fainting
- unusual bleeding or bruising
- fever
- chills
- sore throat
- body aches
- other flu-like symptoms
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Disease interactions
6 potential interactionsApplies to: 6 conditions, including Fever, Liver Disease, Infection, Bleeding Disorder, and Renal Dysfunction.
Bleeding Disorder
Major:thiotepa
Thiotepa has a major potential interaction with Bleeding Disorder.
Thiotepa induces dose-related myelosuppression. Therapy with thiotepa should be withheld if a white blood cell count falls below 3000/mm3 or a platelet count falls below 150,000/mm3. If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.
Bone Marrow Depression/Low Blood Counts
Major:thiotepa
Thiotepa has a major potential interaction with Bone Marrow Depression/Low Blood Counts.
Thiotepa induces dose-related myelosuppression. Therapy with thiotepa should be withheld if a white blood cell count falls below 3000/mm3 or a platelet count falls below 150,000/mm3. If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.
Fever
Major:thiotepa
Thiotepa has a major potential interaction with Fever.
Thiotepa induces dose-related myelosuppression. Therapy with thiotepa should be withheld if a white blood cell count falls below 3000/mm3 or a platelet count falls below 150,000/mm3. If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.
Infection
Major:thiotepa
Thiotepa has a major potential interaction with Infection.
Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.
Liver Disease
Major:thiotepa
Thiotepa has a major potential interaction with Liver Disease.
Thiotepa is rapidly metabolized by the liver to a biologically active form. The pharmacokinetic disposition of thiotepa has not be evaluated in patients with hepatic dysfunction. The use of thiotepa may be contraindicated in patients with existing hepatic damage. If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage. Clinical monitoring of hepatic function is recommended.
Renal Dysfunction
Major:thiotepa
Thiotepa has a major potential interaction with Renal Dysfunction.
Approximately 25% of thiotepa is eliminated by the kidney and <2% is eliminated unchanged in the urine. The pharmacokinetic disposition of thiotepa has not be evaluated in patients with renal dysfunction. The use of thiotepa may be contraindicated in patients with existing renal dysfunction. If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage. Clinical monitoring of renal function is recommended.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.